Articles tagged with Drug Therapy
Researchers found that blocking histamine-releasing factor (HRF) and immunoglobulin E (IgE) interactions may provide relief for patients with severe asthma. The study, published in The Journal of Allergy and Clinical Immunology, suggests two potential therapies, including HRF-2CA and a therapeutic antibody called SPF7-1.
A new research centre will focus on developing new types of RNA medicine for treating metabolic diseases. The centre, led by Professor Jørgen Kjems at Aarhus University, aims to create targeted treatments for conditions like diabetes and atherosclerosis.
Researchers from UTEP School of Pharmacy are exploring a new treatment for vascular dementia using the NIH grant to study the biological triggers behind the condition and test the effectiveness of candidate drug ZT-1a. The treatment aims to prevent cognitive impairments in dementia patients.
A University of Ottawa team has discovered a vital role for the VGLUT3 transporter protein in modulating the development of Huntington's disease. The study shows that blocking glutamate release through this protein can lead to an amelioration of the disease progression, offering new hope for potential treatment approaches.
Two studies investigate long-term consequences of COVID-19, identifying potential drug targets for treating chronic disease. Researchers found novel pathways in the lungs and immune system that may lead to effective treatment options, including therapies targeting immune dysfunction and mucous cell differentiation.
Researchers at Sanford Burnham Prebys have discovered a new treatment for autoimmune diseases using LY3361237, an antibody that activates BTLA to inhibit the immune system. The study provides insight into the molecular biology of the immune system and could lead to the development of more effective therapies.
A supervised hospital walking program has been shown to reduce nursing facility admissions for older adults by lowering the proportion of patients discharged to skilled nursing facilities from 13% to 8%. However, low participation rates and limited impact on length of stay or inpatient falls were noted.
A study published in JAMA Oncology suggests that stopping immunotherapy after two years for patients with advanced non–small cell lung cancer who remain responsive may be a reasonable strategy, providing sustained clinical benefit. The findings provide reassurance for patients and their healthcare providers.
A study found that adding ribociclib to hormone therapy significantly improves invasive disease-free survival rates in patients with stage 2 or 3 HR positive/HER2 negative breast cancer. The combination therapy reduced the risk of cancer recurrence by 25%, with a three-year invasive disease-free survival rate of 90.4%.
A UTHSC research collaboration has been awarded a national grant to develop a new treatment for ovarian cancer. The project will test a newer generation of sabizabulin, a clinical candidate targeting microtubules in cancer cells.
Researchers at the National Human Genome Research Institute identified a potential treatment for disabling pansclerotic morphea, a severe inflammatory disease. They found that patients with the disorder have an overactive STAT4 protein and significantly improved symptoms with ruxolitinib, a JAK inhibitor.
Researchers found that MALAT1 inhibition decreased BRAF RNA and protein levels, while increasing correlation with MAPK-associated genes. MALAT1-ASO treatment also reduced melanoma cell growth and tumor size in xenograft models.
A study by Japanese researchers identifies the involvement of angiotensin II-AT1 and prostaglandin E2-EP1 systems in high-salt-induced hypertension and emotional/cognitive impairment, offering potential therapeutic targets for dementia prevention.
Two researchers will receive $1 million each for their five-year studies on new medication-based approaches to repair damaged aortas, as well as the effects of exercise on healing heart muscle and brain tissue after a heart attack or stroke. The American Heart Association's Merit Award supports innovative research with high impact.
Researchers developed a novel hybrid protein complex by binding lysozyme to copper for enhanced reactive oxygen species (ROS) removal. The CuST@lysozyme hybrid protein showed high SOD activity and stability in biological fluids, paving the way for its therapeutic applications.
Researchers have identified a novel model and therapy to mitigate the development of REM sleep behavior disorder, which affects over 3 million Americans. Dual orexin receptor antagonists have been shown to significantly reduce dream enactment behaviors, providing a promising new treatment option.
Researchers at Weill Cornell Medicine have successfully converted human stomach stem cells into insulin-secreting cells, offering a promising approach to treating type 1 and severe type 2 diabetes. The transplants reversed disease signs in mouse models, suggesting good durability.
The Alzheimer's disease development pipeline has seen an increase in promising therapies and pharma investment, driving momentum in clinical trials. The pipeline currently has 187 clinical trials, with recent FDA approvals for two disease-modifying therapies, and more on the way.
Researchers developed a drug treatment that inhibits YTHDF2, improving results of radiation therapy and preventing progression of distant metastasis. The treatment also prevents the "bad-scopal" effect, where radiation causes distant tumors to metastasize.
A recent study published in JAMA Psychiatry found that fewer boys aged 15-19 commit suicide in Swedish regions with higher bipolar diagnoses. The study, which analyzed registry data from 2008 to 2021, showed an inverse association between population-adjusted bipolar diagnoses and confirmed suicides among males.
Researchers have developed new methods to analyze dry-coated drug particles using 3D Raman mapping, which can effectively slow down dissolution rates. Another study introduces a novel technique for detecting complex traditional Chinese medicines, preventing adulteration and counterfeiting.
Researchers at Rensselaer Polytechnic Institute and Albany Medical College will use AI to develop a novel mesoscopic, multimodal preclinical imaging approach to test the hypothesis that drug distribution mediates tumor resistance. The goal is to improve targeted therapy for HER2-positive breast cancer.
Researchers have found a compound that can prevent cisplatin-induced renal toxicity and improve the outcomes of cancer treatment. The aromatic ketone 2',4',6'-trihydroxyacetophenone (THA) inhibits the CCBL1-mediated metabolism of cisplatin, reducing its toxic effects without affecting its potency.
A study of nearly 67,200 postmenopausal women found that the Fracture Risk Assessment Tool (FRAX) was inadequate for identifying osteoporotic fracture risk across racial/ethnic categories. However, the Osteoporosis Self-Assessment Tool (OST) was excellent for detecting osteoporosis within each category.
A Baylor team created a molecular classifier test to identify patients with HER2-positive breast cancer who may benefit from anti-HER2 therapy alone without chemotherapy. The test accurately predicts the most likely response of a tumor to specific treatment regimens, allowing for personalized de-escalation approaches.
A recent study found that COVID-19 infection can lead to increased infarct growth and ongoing tissue consumption even after successful reperfusion through angiography. This suggests a potentially aggressive clinical course for patients with COVID-19 and large-vessel occlusion acute ischemic stroke.
Researchers at Michigan Medicine have discovered a new nutrient source that pancreatic cancer cells use to grow in the absence of glucose. Uridine is found in the tumor microenvironment and its exact source remains unknown. Blocking uridine metabolism may lead to new treatment options for pancreatic cancer.
Researchers at Dartmouth Cancer Center found that alternating estrogen stimulation and anti-estrogen therapy is an effective treatment for patients with metastatic or advanced ER+ breast cancer. The POLLY trial showed that 42% of patients experienced tumor stabilization, while no patients discontinued treatment due to side effects.
Researchers at Brigham and Women's Hospital have characterized the structure of amyloid-beta fibrils in the human brain, revealing their role in Alzheimer's disease progression. The study sheds light on how lecanemab, a US FDA-approved drug, exerts its protective effects by targeting these fibrils.
A study of 5302 patients found no significant difference in bleeding events between those temporarily discontinuing and maintaining antithrombotic therapy during image-guided breast biopsies. The findings support the safety of continuing antithrombotic therapy, but counsel patients on bruising risk.
Researchers used cancer proteomics data to identify gene candidates for therapeutic targeting, focusing on protein kinases in uterine endometrial cancer cells. Public molecular resources and multi-omics data analysis can prioritize genes of interest for future studies.
Researchers at McMaster University have found that solriamfetol is the most effective treatment for excessive daytime sleepiness (EDS) in individuals with obstructive sleep apnea (OSA). A systematic review of 14 clinical trials and analysis of data from various databases revealed solriamfetol to be the best option.
Scientists have developed a new method to deliver genetic information to stem cells using nanoparticles coated with a specific polymer, enabling more efficient control over cellular differentiation. This innovation has the potential to improve the efficiency and effectiveness of regenerative medicine treatments.
A phase 2 clinical trial testing a treatment combining standard chemotherapy with azacitidine showed nearly 90% of patients with aggressive T-cell lymphoma achieved complete remission. The treatment, which targets gene-silencing marks on DNA, has an estimated two-year progression-free survival rate of 69.2%.
The IOF-ESCEO World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases is the largest international scientific event devoted to musculoskeletal disorders. The congress presents new clinical advances and research on osteoporosis, osteoarthritis, sarcopenia, frailty, and rare skeletal disorders.
Researchers uncover a pathophysiological mechanism that initiates and sustains neuropathic pain in mice, identifying Tiam1 as a potential therapeutic target. Targeting spinal Tiam1 with antisense oligonucleotides alleviates neuropathic pain hypersensitivity, offering promise for treating chronic pain.
Researchers identified three novel dual-purpose therapeutic targets using PandaOmics, which could treat both aging and glioblastoma multiforme. The target hypotheses include cyclic nucleotide gated channel subunit alpha 3 (CNGA3), glutamate dehydrogenase 1 (GLUD1) and sirtuin 1 (SIRT1).
A large study found no difference in cardiovascular outcomes between patients taking beta blockers and those who didn't, after a year of hospital discharge. The researchers suggest reevaluating the value of long-term beta blocker therapy in low-risk heart attack patients with normal functioning hearts.
Researchers have identified 11 somatic mutations in the RAS/MAPK pathway that contribute to treatment-resistant adult epilepsy, suggesting the potential for repurposed anti-cancer agents as new treatments. This study provides insight into the genetic mechanisms underlying this form of epilepsy and opens up new avenues for targeted ther...
A recent study reveals that many children with attention-deficit/hyperactivity disorder (ADHD) are not receiving adequate treatment. The findings highlight the need for improved communication and access to outpatient mental health care for children with ADHD.
Researchers analyzed genetic changes in organs of recently deceased patients with metastatic cutaneous melanoma to understand how the disease spreads and evolves. They found that cancer cells take advantage of specific organ environments, pointing to the need for distinct treatment approaches.
Researchers propose regulations around psychedelic medicine use, including risk evaluation and mitigation strategies, practitioner certifications, and decriminalization of psychedelics. They also emphasize the need for funding clinical trials on naturally occurring psychedelics to ensure a pathway for approval.
Researchers investigated the roles of STAT3α and STAT3β in aggressive breast cancer and found that differential silencing of these isoforms leads to changes in STAT3 activation. This study emphasizes the importance of distinguishing between STAT3 isoforms for accurate cancer diagnosis and therapy.
Researchers at Temple University Health System found that carbonic anhydrase inhibitors reduce inflammation, restore cell function and prevent cognitive impairment in mice with amyloid buildup. CAIs also improved cerebrovascular health and enhanced amyloid-clearing capacity.
A study by Michigan Medicine researchers found that nitrous oxide, LSD, and ketamine induce similar changes in brain connectivity, particularly in the cortical 'hot zone' where conscious experience is determined. This common biology may hold the key to using psychedelics as therapeutics.
A majority of people over 50 are open to stopping one or more prescription medicines, but many don't discuss it with their health provider first. The poll shows that comprehensive medication reviews and cost considerations play a crucial role in deprescribing conversations.
Researchers developed a gene signature called CisSig to predict cancer patients' response to cisplatin. The approach aims to overcome the obstacle of interpreting gene signatures in the human body and has been validated in muscle-invasive bladder cancer patients.
The 18th Key Symposium on Healthy Ageing and Longevity takes place in Okinawa, bringing together world experts to discuss the latest research on blue zones. The symposium aims to promote both longevity and healthy ageing to reduce age-related diseases and healthcare burden.
Researchers found that bad medical news can make patients more likely to choose brand name drugs over generics, resulting in increased healthcare expenditures. The study suggests that simply reminding patients of the equivalency of generic drugs via text message could improve their decision-making.
A new study by Brigham researchers found that 27 high-selling brand-name drugs provided little added clinical benefits despite high costs. The results suggest that Medicare can negotiate prices based on the added benefits of these drugs.
Researchers at UMass Amherst microbiologists have identified an enzyme involved in TB pathogen's survival and growth. The discovery offers a potential target for drug therapies for the deadly disease, which has few effective treatments and caused over 1.6 million deaths worldwide in 2021.
A team of researchers has discovered that a naturally produced chemical in the body helps glioblastoma cells go unrecognized by the immune system. The findings could lead to the development of new and more effective treatments for this aggressive brain cancer.
A new target for drug-resistant ovarian cancer has been identified through a preclinical study led by researchers at Penn Medicine. An antibody-drug conjugate targeting B7-H4 showed significant anti-tumor activity and sustained response in treatment-resistant models.
Researchers develop mechanical nanosurgery to destroy tumour cells from within, reducing GBM tumour size universally, including in TMZ-resistant cases. The treatment uses magnetically controlled carbon nanotubes to provide mechanical stimulation, damaging cellular structures and causing tumour cell death.
A study of over 43,000 adults found that parathyroidectomy has no estimated effect on long-term kidney function in older adults. However, early treatment may preserve kidney function in patients younger than 60 years old.
Researchers developed a chelator-free-radiolabeled polymersome capable of long-term multiday PET imaging in vivo. The nanovesicle meets key requirements for targeted cancer therapy, including precision targeting, stable radiotracer binding, and biocompatibility.
The new guidelines, developed by 22 experts across three continents, provide a comprehensive approach to diagnosing and treating catatonia. The recommendations include the use of benzodiazepines and electroconvulsive therapy, with attention to special requirements for certain groups.
A new study reveals that targeting the SWI/SNF protein complex can disrupt PU-1-directed enhancer programs in AML cells, leading to therapeutic responses and rapid tumor regression. The findings also show that these inhibitors have manageable side effects on normal blood cells.
A team of scientists from City University of Hong Kong and HKUST discovered novel, tridimensional compounds with high anticancer activity and low toxicity. These compounds can overcome drug resistance in cancer cells by inducing a different cell death pathway.
Researchers have identified a biomarker signature that can predict which patients with kidney cancer will respond well to immunotherapy. The signature is based on the number of immune cells in and around tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1.